BRPI0813262A2 - Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a - Google Patents

Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a

Info

Publication number
BRPI0813262A2
BRPI0813262A2 BRPI0813262A BRPI0813262A2 BR PI0813262 A2 BRPI0813262 A2 BR PI0813262A2 BR PI0813262 A BRPI0813262 A BR PI0813262A BR PI0813262 A2 BRPI0813262 A2 BR PI0813262A2
Authority
BR
Brazil
Prior art keywords
joint
biomarkers
disease therapy
inflammatory
destruction
Prior art date
Application number
Other languages
English (en)
Inventor
Edward Paul Bowman
Cheng-Chi Chao
Shi-Juan Chen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0813262A2 publication Critical patent/BRPI0813262A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0813262 2007-06-20 2008-06-20 Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a BRPI0813262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94523907P 2007-06-20 2007-06-20
PCT/US2008/007770 WO2008156865A2 (en) 2007-06-20 2008-06-20 Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease

Publications (1)

Publication Number Publication Date
BRPI0813262A2 true BRPI0813262A2 (pt) 2015-04-14

Family

ID=39858472

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813262 BRPI0813262A2 (pt) 2007-06-20 2008-06-20 Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a

Country Status (9)

Country Link
US (1) US20100239590A1 (pt)
EP (1) EP2171449A2 (pt)
JP (1) JP5237366B2 (pt)
CN (1) CN101932935A (pt)
AU (1) AU2008266745B2 (pt)
BR (1) BRPI0813262A2 (pt)
CA (1) CA2690568A1 (pt)
CO (1) CO6351824A2 (pt)
WO (1) WO2008156865A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288382B1 (en) 2008-05-05 2018-08-29 NovImmune SA Anti- il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2384367A4 (en) * 2008-12-30 2013-07-10 Janssen Biotech Inc SERUM MARKERS TO PREDICT THE CLINICAL RESPONSE TO ANTI-TNF ANTIBODIES IN PATIENTS WITH MORBUS BECHTEREW
AU2011233753A1 (en) * 2010-03-31 2012-09-13 Anamar Ab Method to detect tissue degradation leading to inflammation
CA2813849C (en) * 2010-11-05 2021-06-15 Novartis Ag Secukinumab for use in the treatment of ankylosing spondylitis
CA2856252A1 (en) * 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2014208645A1 (ja) * 2013-06-28 2014-12-31 中外製薬株式会社 そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
WO2015009754A2 (en) 2013-07-15 2015-01-22 Svoboda Steven J Methods and apparatus for assessment of risk for joint injury
WO2015048842A1 (en) * 2013-10-04 2015-04-09 Cell Ideas Pty Ltd Biomarkers for cell therapy
WO2015132241A1 (en) * 2014-03-03 2015-09-11 Novo Nordisk A/S Treatment of inflammatory diseases
US20160125142A1 (en) * 2014-11-05 2016-05-05 Omar Awad Interactive Electronic Health Record System for Retrieving, Reviewing, and Updating Health Records at the Point of Care
AU2020237509A1 (en) * 2019-03-12 2021-08-05 Novus International Inc. Biomarkers for joint ailments and uses thereof
US20220340660A1 (en) * 2019-10-01 2022-10-27 Merck Sharp & Dohme Corp. Biomarkers for anti-tigit antibody treatment
CN114518416B (zh) * 2020-11-20 2024-05-24 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
DE69727582T2 (de) * 1996-08-15 2004-12-23 Novartis Ag Test zur quantifizierung von arthritiszustanden
DE69738841D1 (de) * 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
US20040171109A1 (en) * 2000-11-10 2004-09-02 Dominik Haudenschild IL-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20040203072A1 (en) * 2002-11-08 2004-10-14 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
JP2008508858A (ja) * 2004-05-13 2008-03-27 イムクローン システムズ インコーポレイティド マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
AU2005254998B2 (en) * 2004-06-10 2011-10-27 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
ATE497508T1 (de) * 2004-10-01 2011-02-15 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
EP1824882B1 (en) * 2004-12-13 2012-02-08 Cephalon Australia (VIC) Pty Ltd Osteoprotegerin variant proteins
CN102178953A (zh) * 2005-02-14 2011-09-14 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
DE102005029845B4 (de) * 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
PL1931697T3 (pl) * 2005-09-28 2011-03-31 Zymogenetics Inc Antagoniści interleukiny IL-17A i IL-17F oraz sposoby ich zastosowania
ES2347840T3 (es) * 2006-02-10 2010-11-04 Zymogenetics, Inc. Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion.
EP1996622A2 (en) * 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
MX2009001620A (es) * 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.

Also Published As

Publication number Publication date
AU2008266745B2 (en) 2014-04-17
AU2008266745A1 (en) 2008-12-24
US20100239590A1 (en) 2010-09-23
JP5237366B2 (ja) 2013-07-17
CA2690568A1 (en) 2008-12-24
JP2010530972A (ja) 2010-09-16
WO2008156865A3 (en) 2009-03-12
CO6351824A2 (es) 2011-12-20
EP2171449A2 (en) 2010-04-07
WO2008156865A2 (en) 2008-12-24
CN101932935A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
BRPI0813262A2 (pt) Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0715917A2 (pt) Anticorpos para il-17a
FR2913672B1 (fr) Joint thermoscellable
DE602007000631D1 (de) Schieblehre
BRPI0722200A2 (pt) Método para calibração de setores
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0810559A2 (pt) Macadores de doenças
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
FR2907178B1 (fr) Joint homocinetique
BRPI0814074A2 (pt) Método para a fabricação de 4-isopropil-3-metilfenol e sua utilização
FR2897662B1 (fr) Joint homocinetique
ES1063735Y (es) Testero para persiana
ES1065835Y (es) Caperuza para cetreria
FR2915546B1 (fr) Joint coulissant
ES1060574Y (es) Separador autoestatico para cirugia
ES1059526Y (es) Posicionador de tuberias para electrosoldadura
ES1065969Y (es) Pieza prefabricada para la construccion de tabiques
ES1066482Y (es) Pieza constructiva para paramento
ES1066110Y (es) Tabique para la construccion
ES1061654Y (es) Bloques prefabricados para escolleras
ES1061780Y (es) Perfiles geometricos para rizos
ES1062073Y (es) Aparato para la recoleccion de la aceituna.
ES1063389Y (es) Embalaje-expositor para tuberias
PT10088T (pt) Fralda para incontinencia

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.